by: David Hutton
According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% (XDEMVY) is the first approved therapeutic for Demodex blepharitis and has demonstrated efficacy across multiple clinical measures of the disease.
Tarsus Pharmaceuticals Inc. announced that the FDA approved lotilaner ophthalmic solution 0.25% (XDEMVY) for the treatment of Demodex blepharitis. Lotilaner ophthalmic solution 0.25%, formerly known as TP-03, is the first and only FDA-approved treatment to directly target Demodex mites, the root cause of Demodex blepharitis.
“We are thrilled to announce the FDA approval of XDEMVY for the treatment of Demodex blepharitis and look forward to making this product broadly available to the millions of patients who have not had any FDA-approved therapeutics for this disease,” Bobak Azamian, MD, PhD, CEO and chairman of Tarsus, said in a news release. “This tremendous milestone was achieved through a successful collaboration of our talented Tarsus team, countless eye care providers, and the hundreds of patients who participated in our trials. We are grateful and honored for the opportunity to introduce the first and only approved therapeutic for this disease to the eye care community.”…
Read more: https://www.ophthalmologytimes.com/view/breaking-news-fda-approves-xdemvy-for-treatment-of-demodex-blepharitis
Source: Ophthalmology Times